Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 1:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 31 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: TKI258 Clear all
Terminated Phase 1 Interventional

Safety, Pharmacokinetics and Pharmacodynamics of TKI258 in Subjects With Acute Myeloid Leukemia

NCT00279773
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
TKI258
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 30, 2010 · Synced Oct 21, 2026, 1:45 AM EDT
Withdrawn Phase 2 Interventional

A Study of Dovitinib With Androgen Deprivation Therapy (ADT) in Patients With Metastatic Prostate Cancer Receiving Primary ADT

NCT02065323
View directory record Official record
Conditions
Prostate Cancer
Interventions
Standard ADT, Dovitinib
Drug
Lead sponsor
Oscar Goodman, Jr.
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jan 19, 2015 · Synced Oct 21, 2026, 1:45 AM EDT
Completed Phase 2Phase 3 Interventional Results available

An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective

NCT02116803
View directory record Official record
Conditions
Solid Tumors
Interventions
dovitinib, fulvestrant
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Las Vegas, Nevada • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 1, 2018 · Synced Oct 21, 2026, 1:45 AM EDT
Completed Phase 1Phase 2 Interventional

Safety of TKI258 in Advanced/Metastatic Melanoma Subjects

NCT00303251
View directory record Official record
Conditions
Melanoma
Interventions
TKI258
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
3
States / cities
Louisville, Kentucky • Pittsburgh, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 11, 2021 · Synced Oct 21, 2026, 1:45 AM EDT
Completed Phase 2 Interventional

Phase II Study of TKI258 in Advanced Urothelial Carcinoma

NCT00790426
View directory record Official record
Conditions
Urothelial Cancer
Interventions
TKI258
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
8
States / cities
La Jolla, California • Los Angeles, California • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 21, 2026, 1:45 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

NCT01379534
View directory record Official record
Conditions
Solid Tumors and Advanced Endometrial Cancer, Endometrial Cancer, Second-line Treatment, VEGF
Interventions
TKI258
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
21
States / cities
Mobile, Alabama • Fullerton, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated May 20, 2015 · Synced Oct 21, 2026, 1:45 AM EDT
Completed Phase 2 Interventional Results available

TKI258 in Castrate Resistant Prostate Cancer

NCT00831792
View directory record Official record
Conditions
Prostate Cancer
Interventions
TK1258
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Oct 21, 2026, 1:45 AM EDT
Completed Phase 1 Interventional

Bioavailability and Food Effect Study of TKI258 (CSF Capsules vs. FMI Capsules)in Adult Patients With Advanced Solid Tumors

NCT01030055
View directory record Official record
Conditions
Neoplasms, Cancer, Tumors
Interventions
TKI258 (dovitinib)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
4
States / cities
Duarte, California • Los Angeles, California • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Oct 21, 2026, 1:45 AM EDT
Completed Phase 1 Interventional

Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors

NCT01596647
View directory record Official record
Conditions
Advanced Solid Tumors, Excluding Breast Cancer
Interventions
caffeine, diclofenac, omeprazole, midazolam, TKI258
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
5
States / cities
Kansas City, Kansas • Detroit, Michigan • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Oct 21, 2026, 1:45 AM EDT
Terminated Phase 2 Interventional Results available

Dovitinib (TKI258) and Abiraterone Acetate in Metastatic Castrate-Resistant Prostate Cancer (mCRPC)

NCT01994590
View directory record Official record
Conditions
Prostate Cancer
Interventions
Dovitinib, Abiraterone Acetate, Prednisone
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Oct 21, 2026, 1:45 AM EDT
Terminated Phase 2 Interventional Results available

TKI 258 in Von Hippel-Lindau Syndrome (VHL)

NCT01266070
View directory record Official record
Conditions
Von Hippel-Lindau Syndrome
Interventions
Dovitinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 13, 2017 · Synced Oct 21, 2026, 1:45 AM EDT
Completed Phase 2 Interventional Results available

Study of Dovitinib (TKI258) in Adenoid Cystic Carcinoma

NCT01524692
View directory record Official record
Conditions
Adenoid Cystic Carcinoma
Interventions
Dovitinib (TKI258)
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 9, 2018 · Synced Oct 21, 2026, 1:45 AM EDT
Completed Phase 1 Interventional

Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers

NCT01497392
View directory record Official record
Conditions
Adenocarcinoma of the Pancreas, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
dovitinib lactate, gemcitabine hydrochloride, capecitabine, laboratory biomarker analysis, enzyme-linked immunosorbent assay, pharmacological study
Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 22, 2022 · Synced Oct 21, 2026, 1:45 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of TKI258 in Relapsed or Refractory Multiple Myeloma Patients, Who Are With or Without t(4;14) Chromosomal Translocation

NCT01058434
View directory record Official record
Conditions
Relapsed or Refractory Multiple Myeloma
Interventions
TKI258
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
15
States / cities
Mobile, Alabama • Alhambra, California • Santa Maria, California + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 21, 2026, 1:45 AM EDT
Terminated Phase 1 Interventional

TKI258 in Subjects With Refractory or Relapsed Multiple Myeloma

NCT00243763
View directory record Official record
Conditions
Multiple Myeloma
Interventions
TKI258
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
5
States / cities
Scottsdale, Arizona • Tampa, Florida • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2009 · Synced Oct 21, 2026, 1:45 AM EDT
Terminated Phase 1 Interventional

Phase 1 Erlotinib and Dovitinib (TKI258) in Advanced Non-small Cell Lung Cancer (NSCLC)

NCT01515969
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC), Recurrent, Non-small Cell Lung Cancer (NSCLC), Stage IV
Interventions
Erlotinib hydrochloride, Dovitinib lactate
Drug
Lead sponsor
Heather Wakelee
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Oct 21, 2026, 1:45 AM EDT
Completed Phase 3 Interventional Results available

Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma

NCT01223027
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma
Interventions
Dovitinib, Sorafenib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
34
States / cities
Fayetteville, Arkansas • La Jolla, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2015 · Synced Oct 21, 2026, 1:45 AM EDT
Completed Phase 2 Interventional Results available

Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib

NCT01831726
View directory record Official record
Conditions
Tumor Pathway Activations Inhibited by Dovitinib
Interventions
Dovitinib (TKI258)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
49
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Pismo Beach, California + 43 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Oct 21, 2026, 1:45 AM EDT
Terminated Phase 1 Interventional

Phase Ib Study of Gemcitabine Plus Cisplatin or Carboplatin Plus Dovitinib in Patients With Advanced Solid Tumors

NCT01496534
View directory record Official record
Conditions
Solid Tumors, Bladder Cancer
Interventions
Cisplatin, Carboplatin
Drug
Lead sponsor
Matthew Galsky
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 27, 2013 · Synced Oct 21, 2026, 1:45 AM EDT
Completed Phase 2 Interventional Results available

Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma

NCT01753713
View directory record Official record
Conditions
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
Interventions
dovitinib, laboratory biomarker analysis
Drug · Other
Lead sponsor
Manmeet Ahluwalia, MD
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Oct 21, 2026, 1:45 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer

NCT01484041
View directory record Official record
Conditions
Breast Cancer
Interventions
Dovitinib, Aromatase Inhibitors
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 9, 2018 · Synced Oct 21, 2026, 1:45 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of TKI258 in FGFR1 Amplified and Non-amplified Metastatic HER2 Negative Breast Cancer

NCT00958971
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
TKI258
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
18
States / cities
Bakersfield, California • Beverly Hills, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 21, 2026, 1:45 AM EDT
Completed Phase 1 Interventional

Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function

NCT01443481
View directory record Official record
Conditions
Solid Tumors, Hepatic Impairment
Interventions
Dovitinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
3
States / cities
Los Angeles, California • Durham, North Carolina • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Oct 21, 2026, 1:45 AM EDT
Completed Phase 1 Interventional

Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors.

NCT01700270
View directory record Official record
Conditions
Advanced Solid Tumors, Excluding Breast Cancer
Interventions
dovitinib (TKI258), fluvoxamine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
The Bronx, New York • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Oct 21, 2026, 1:45 AM EDT